Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

191.85 +1.69 (+0.89%)

Streaming Delayed Price Updated: 12:28 PM EDT, Jul 7, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	731,609
Open	192.98
Bid (Size)	191.77 (200)
Ask (Size)	191.85 (100)
Prev. Close	190.16
Today's Range	191.60 - 193.79
52wk Range	173.66 - 212.71
Shares Outstanding	N/A
Dividend Yield	0.48%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

IEFA vs. VXUS: Both Are Cheap. Both Are Broad. Here Is the Key Difference Long-Term Investors Need to Understand. ↗

July 02, 2026

These international stock ETFs from iShares and Vanguard are very different once you look under the surface.

Via The Motley Fool

AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care

June 24, 2026

From AstraZeneca

Via Business Wire

Performance

YTD	+1.8%	+1.8%
1 Month	+5.7%	+5.7%
3 Month	-5.4%	-5.4%
6 Month	+1.8%	+1.8%
1 Year	+1.8%	+1.8%

More News

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies

June 22, 2026

Via Investor Brand Network

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

June 22, 2026

Via Investor Brand Network

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

June 12, 2026

From AstraZeneca

Via Business Wire

IXUS vs. IEFA: Which International ETF Is Better for Most Investors? ↗

June 10, 2026

Via The Motley Fool

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial

June 02, 2026

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

June 01, 2026

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

May 28, 2026

From AstraZeneca

Via Business Wire

Marathon Halves Its Copa Stake—The Panama Hub Advantage Still Stands ↗

May 23, 2026

Via The Motley Fool

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

May 22, 2026

From AstraZeneca

Via Business Wire

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

May 22, 2026

From AstraZeneca

Via Business Wire

3 International ETFs for Investors Looking Beyond U.S. Stocks ↗

May 18, 2026

Via The Motley Fool

As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade ↗

May 18, 2026

Via MarketBeat

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

May 18, 2026

From AstraZeneca

Via Business Wire

M&G Shaved 2.4% of Methanex After a Near-Doubling ↗

May 17, 2026

Via The Motley Fool

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer

May 15, 2026

From AstraZeneca

Via Business Wire

Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial

May 14, 2026

From AstraZeneca

Via Business Wire

This Low-Cost ETF Holds Almost 8,800 Stocks Across Both Developed and Emerging Markets. Here's Why It's a Compelling Long-Term Core Holding ↗

May 07, 2026

Via The Motley Fool

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat ↗

May 02, 2026

Via MarketBeat

TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer

April 30, 2026

From AstraZeneca

Via Business Wire

AstraZeneca results: Q1 2026

April 29, 2026

From AstraZeneca

Via Business Wire

BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older

April 28, 2026

From AstraZeneca

Via Business Wire

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

April 27, 2026

From AstraZeneca

Via Business Wire

Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗

April 27, 2026

Via The Motley Fool

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?

Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.

What exchange does AstraZeneca PLC - American Depositary Shares trade on?

AstraZeneca PLC - American Depositary Shares trades on the New York Stock Exchange

What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?

The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the New York Stock Exchange

What is the current price of AstraZeneca PLC - American Depositary Shares?

The current price of AstraZeneca PLC - American Depositary Shares is 191.85

When was AstraZeneca PLC - American Depositary Shares last traded?

The last trade of AstraZeneca PLC - American Depositary Shares was at 07/07/26 12:28 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.